Parklands Way, Eurocentral
About TC BioPharmTC BioPharm (TCB) is an immunotherapy company developing novel cell based products for treatment of cancer and severe viral infections. TCB employs a team of over 40 staff and acts as a fully integrated pharmaceutical company encompassing GMP Manufacture, quality, product development, regulatory affairs and in-house clinical research.
Founders: Michael Leek, Artin Moussavi, Angela Scott, and David Gallagher
Founder and CEO: Michael Leek
Founder and CBO: Artin Moussavi
Founder and COO: Angela Scott
Please click here for TC BioPharma job opportunities.
FOLLOW TC BIOPHARM:
Tweets by TC BioPharm
8 articles with TC BioPharm
Companies across Europe and Asia provide information about deal, clinical trials and more, with news from Synaptive Medical, Epic, Inventiva, Velabs, and more.
TC BioPharm Initiates Phase I Trial of Allogeneic Gamma Delta T Cell Therapy in Acute Myeloid Leukemia Patients
Study to provide safety data on allogeneic use of GDTs prior to subsequent use of CAR-modified variants
The first completed bio-banks will be used to develop more cost-effective, safe and efficacious cancer treatments
TC BioPharm has announced it is opening of a new office in Japan to continue expansion of its Asian operations.
TC Biopharm and the Nipro Corporation Announce Strategic Programme Co-Developing a Novel Gamma-Delta Car-T Product to Treat Cancer
TCB intends to use this novel platform to develop new CA-based immunotherapies, with the aim of treating a broad range of cancers and major viral disease
bluebird bio and TC BioPharm Announce Strategic Collaboration to Research and Develop Gamma Delta CAR T Cell Product Candidates for Cancer Immunotherapy
Under the terms of the agreement, bluebird bio and TCB will collaborate to discover and develop CAR-engineered gamma delta T cells for cancer targets and indications.
TC BioPharm Selected For EU Horizon 2020 Funding To Progress Novel, Mass-Market Cell Therapies To Clinical Trial